Quick Answer
PharmaCyte Biotech, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
PharmaCyte Biotech, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $30.66M +9085.0% |
$333.8K +107.7% |
-$4.32M -1.8% |
-$4.24M -19.4% |
-$3.55M +7.2% |
-$3.83M +5.9% |
| Diluted EPS | $3.19 +277.2% |
-$1.80 -718.2% |
-$0.22 +18.5% |
-$0.27 +89.0% |
-$2.45 | — |
| Total Assets | $55.17M -7.9% |
$59.90M -18.3% |
$73.28M -19.1% |
$90.62M +1124.0% |
$7.40M +20.1% |
$6.17M +6.6% |
| Cash and Equivalents | $15.17M -69.8% |
$50.18M -26.2% |
$68.04M -20.3% |
$85.40M | — | — |
| Stockholders Equity | $51.89M +87.7% |
$27.65M -62.0% |
$72.69M -19.2% |
$89.92M +1246.2% |
$6.68M +31.3% |
$5.09M +1.0% |
| R&D Expense | $438.4K +7.6% |
$407.4K -13.0% |
$468.5K -32.2% |
$690.9K -24.6% |
$916.2K +204.2% |
$301.2K -34.5% |
| Operating Income | -$4.38M +48.6% |
-$8.52M -32.0% |
-$6.46M -47.0% |
-$4.39M -21.2% |
-$3.62M +5.3% |
-$3.83M +6.7% |
| Gross Profit | — | — | — | — | — | — |
| Shares Outstanding | 6.80M -15.5% |
8.04M -52.1% |
16.79M -19.0% |
20.72M +1203.1% |
1.59M +45.6% |
1.09M -99.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | January 31, 2026 | $0.00 | — | — |
| Net Income | January 31, 2026 | $746.9K | +124.5% | +110.1% |
| Diluted EPS | January 31, 2026 | -$0.17 | +61.4% | +86.3% |
| Total Assets | January 31, 2026 | $55.87M | +27.5% | -0.2% |
| Cash and Equivalents | January 31, 2026 | $20.17M | +23.1% | +30.9% |
| Long-Term Debt | January 31, 2012 | $247.9K | — | — |
| Stockholders Equity | January 31, 2026 | $38.11M | -5.3% | +8.2% |
| R&D Expense | January 31, 2026 | $93.1K | -21.2% | -34.0% |
| Operating Income | January 31, 2026 | -$2.12M | -120.6% | -53.9% |
| Gross Profit | October 31, 2016 | $0.00 | — | — |
| Shares Outstanding | January 31, 2026 | 10.74M | +55.5% | +58.0% |
- PharmaCyte Biotech, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
- PharmaCyte Biotech, Inc. reported Net Income of $30.66 million for fiscal year 2025.
- PharmaCyte Biotech, Inc. showed an increase of +9085.0% in Net Income compared to the prior fiscal year.
- PharmaCyte Biotech, Inc. reported Diluted EPS of $3.19 per share for fiscal year 2025.
- PharmaCyte Biotech, Inc. showed an increase of +277.2% in Diluted EPS compared to the prior fiscal year.
- PharmaCyte Biotech, Inc. reported Total Assets of $55.17 million for fiscal year 2025.
- PharmaCyte Biotech, Inc. showed a decrease of -7.9% in Total Assets compared to the prior fiscal year.
- PharmaCyte Biotech, Inc. reported Cash and Equivalents of $15.17 million for fiscal year 2025.
- PharmaCyte Biotech, Inc. showed a decrease of -69.8% in Cash and Equivalents compared to the prior fiscal year.
- PharmaCyte Biotech, Inc. reported Stockholders Equity of $51.89 million for fiscal year 2025.
- PharmaCyte Biotech, Inc. showed an increase of +87.7% in Stockholders Equity compared to the prior fiscal year.
- PharmaCyte Biotech, Inc. reported R&D Expense of $438.4 thousand for fiscal year 2025.
- PharmaCyte Biotech, Inc. showed an increase of +7.6% in R&D Expense compared to the prior fiscal year.
- PharmaCyte Biotech, Inc. reported Operating Income of -$4.38 million for fiscal year 2025.
- PharmaCyte Biotech, Inc. showed an increase of +48.6% in Operating Income compared to the prior fiscal year.
- PharmaCyte Biotech, Inc. reported Gross Profit of $0.00 for fiscal year 2016.
- PharmaCyte Biotech, Inc. reported Shares Outstanding of 6.80 million shares for fiscal year 2025.
- PharmaCyte Biotech, Inc. showed a decrease of -15.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: